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Abstract
Background: Cyclooxygenase (COX) is the rate-limiting enzyme that catalyzes the formation of
prostaglandins. The inducible isoform of COX (COX-2) is highly expressed in aggressive metastatic
breast cancers and may play a critical role in cancer progression (i.e. growth and metastasis).
However, the exact mechanism(s) for  COX-2-enhanced metastasis has yet to be clearly defined.
It is well established that one of the direct results of COX-2 action is increased prostaglandin
production, especially prostaglandin E2 (PGE2). Here, we correlate the inhibition of COX-2 activity
with decreased breast cancer cell proliferation, migration, invasion and matrix metalloproteinase
(MMP) expression.
Methods: Breast cancer cells (Hs578T, MDA-MB-231 and MCF-7) were treated with selective
COX-2 inhibitors (NS-398 and Niflumic acid, NA). Cell proliferation was measured by staining with
erythrosin B and counting the viable cells using a hemacytometer. Cell migration and invasion were
measured using migration and invasion chamber systems. MMP expression was determined by
enzyme immunoassay (secreted protein) and real-time quantitative polymerase chain reaction
(mRNA).
Results: Our results show that there is a decline in proliferation, migration and invasion by the
Hs578T and MDA-MB-231 breast cancer cell lines in the presence of either low concentrations (1
μM or lower) NA or NS-398. We also report that MMP mRNA and protein expression by Hs578T
cells is inhibited by NS-398; there was a 50% decrease by 100 μM NS-398. PGE2 completely
reversed the inhibitory effect of NS-398 on MMP mRNA expression.
Conclusion: Our data suggests that COX-2-dependent activity is a necessary component for
cellular and molecular mechanisms of breast cancer cell motility and invasion. COX-2 activity also
modulates the expression of MMPs, which may be a part of the molecular mechanism by which
COX-2 promotes cell invasion and migration. The studies suggest that COX-2 assists in
determining and defining the metastatic signaling pathways that promote the breast cancer
progression to metastasis.
Published: 10 July 2006
BMC Cancer 2006, 6:181 doi:10.1186/1471-2407-6-181
Received: 14 January 2006
Accepted: 10 July 2006
This article is available from: http://www.biomedcentral.com/1471-2407/6/181
© 2006 Larkins et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 12
(page number not for citation purposes)
BMC Cancer 2006, 6:181 http://www.biomedcentral.com/1471-2407/6/181Background
Numerous studies indicate that cyclooxygenase-2 (COX-
2) is highly expressed in a variety of human cancers,
including colorectal, breast and prostate. In breast cancer,
the expression of the COX-2 gene is associated with high
tumor grade [1], which suggests it may serve as a prognos-
tic biomarker for the presence of breast cancer. Research-
ers also found high expression of COX-2 in highly
invasive estrogen independent breast cancer cell lines,
(MDA-MB-231 (MDA-231) and Hs578T) as well as 12, 0-
tetradecanoylphorbol-13-acetate (TPA)-induced COX-2
expression, while a poorly invasive and estrogen depend-
ent cell line (MCF-7) did not express COX-2 [2,2,3]. Rista-
maki et al. [4] also confirmed that the elevated COX-2
expression seen in 37.4% of the 1567 invasive breast can-
cers were associated with a large tumor size, high tumor
grade, negative estrogen receptor status, high p53 expres-
sion and unfavorable prognosis. Transgenic mice that
overexpressed COX-2 in mammary epithelial cells pro-
moted mammary gland tumorigenesis and decreased
apoptosis by reducing the expression levels of proapop-
totic genes [4,5]. When transfecting the breast cancer cell
line, MDA-MB-435 with COX-2, the cells migrated signif-
icantly better than the untransfected control cells [6]. The
expression of COX-2 in breast tumors can be correlated
with high metastatic potential.
Many of the critical steps of malignant tumorigenesis,
such as cell proliferation, evading apoptosis, stimulating
angiogenesis, enhancing cell motility, cell invasiveness
and mediating immune suppression, have been associ-
ated with cyclooxygenase-2 expression. The end-products
of COX-2 activity are prostaglandins and thromboxanes
which may mediate these changes in cancer cell progres-
sion.
Elevated levels of prostaglandins, notably PGE2, have
been detected in breast cancer cell lines, as well as invasive
breast cancer [3,7,8]. Gilhooly et al. [2] induced COX-2
expression and activity in breast cancer cell lines with TPA
which increased the production of PGE2. PGE2 was shown
to stimulate cell proliferation indirectly by increasing
estrogen levels via the induction of the aromatase gene
expression [9]. Other researchers have shown that PGE2,
prostacyclin and thromboxanes A2 contribute to tumor
angiogenesis by mediating endothelial cell migration
through integrin αVβ3 and by aiding in the production of
angiogenic growth factors [10,11].
Recent data suggest a correlation between COX-2 expres-
sion and cell invasiveness. In order for cancer cells to
metastasize, the cells must digest and dissolve the extracel-
lular matrix (ECM) and the basement membrane, which
requires the secretion and activation of MMPs. The expres-
sion and activation of MMPs may be directly proportional
to the overexpression of COX-2 in tumor cells. One group
has shown that Hs578T breast cancer cells transfected
with COX-2 resulted in the activation of MMP-2 [12].
Sivula et al. [13] found increased COX-2 expression in
breast cancer specimens, which also exhibited elevated
MMP-2 expression and decreased disease specific survival.
MMP-2 was elevated in 56 out of 59 invasive breast carci-
nomas in which expression of COX-2 was moderate to
high. Studies also suggest that COX-2 may mediate uroki-
nase plasminogen activator (uPA) production in meta-
static breast cancer cell lines that overexpress COX-2. The
uPA activates proteases and MMPs that degrade the base-
ment membrane and mediate cytoskeleton reorganiza-
tion. [6,12,14].
To our knowledge, we are the first to report evidence that
COX-2 activity and expression may modulate the expres-
sion and activity of several MMPs in COX-2 expressing
breast cancer cells. In this study, we screened for eight
MMPs in breast cancer cells that were treated with and
without of a COX-2 inhibitor. To date, only three groups
have reported on studies focused only on the effect of
COX-2 activity on the secretion of the gelatinases (MMP-
2 and -9); all were done on cancers other than breast.
Attiga et al. [15] have reported the inhibition of MMP-2
and MMP-9 by COX-2 inhibitors in prostate cancer. Tsuji
et al. [16] observed an increase in MMP-2 activation and
increase in MMP-14 mRNA expression by Caco-2 colon
cancer cells, which showed high levels of COX-2. MMP-2
levels were decreased in the non-small cell lung cancer cell
lines, A549 and H157 when treated with a COX-2 specific
inhibitor [17].
The results of a number of epidemiological, clinical and
laboratory studies suggest that the administration of COX
inhibitors (NSAIDs, aspirin, indomethacin) reduces the
incidence of breast, colon and prostate cancers [15,18-
23]. Although several researchers have reported on the
association of COX-2 overexpression with tumorigenesis
in various cancers, many do not address the mechanism
by which COX-2 promotes tumorigenesis. Using COX-2
inhibitors to prevent tumorigenesis will allow us to study
the properties of COX-2 that influence breast cancer
metastasis. The aim of the study reported here was to fur-
ther elucidate the mechanism in which COX-2 promotes
metastasis by using COX-2 selective inhibitors to study
the role of COX-2 breast cancer motility and invasion. We
were able to demonstrate that low and achievable concen-
trations of specific COX-2 inhibitors were sufficient to
reduce the proliferation, migration and invasion of COX-
2 expressing breast cancer cells. This study also suggests
that COX-2 modulates the expression and activity of mul-
tiple MMPs involved in breast cancer metastasis.Page 2 of 12
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Cell lines and cell culture
The Hs578T, MDA-231 and MCF-7 breast cancer cell lines
were all obtained from the American Type Culture Collec-
tion (Manassas, VA). The Hs578T and MDA-231 are estro-
gen-independent and highly invasive breast cancer cells.
Although there have been studies that have looked at the
expression of COX-2 in these breast cancer cell lines
[2,3,24], we wanted to be certain that under our experi-
mental conditions we saw similar results. We found high
expression of COX-2 by both cell lines (Fig. 1). The MCF-
7 cell line is an estrogen-dependent and poorly invasive
breast cancer cell line that did not express COX-2. All cell
lines were adapted for growth in Dulbecco's modified
Eagle's medium (DMEM, Cambrex-Biowhittaker Walkers-
ville, MD) supplemented with 0.1 Unit/ml bovine insulin
(Sigma Chemical Co. St. Louis, MO), 100 I. U. penicillin,
100 μg/ml streptomyocin, 0.25 μg/ml amphotericin B
(Cellgro Herndon, VA) and 10% fetal bovine serum (FBS
Hyclone, Logan UT). When cells reached confluency, the
cells were harvested by trypsinizing with 0.25% trypsin,
2.21 mM EDTA-Na in Hank's Balanced Salt solution w/
Ca2+, Mg2+ and NaHCO3 (Cellgro Herndon, VA), pelleted,
resuspended in fresh medium and seeded in multiple 75-
cm2 flasks (Corning Corning, NY).
Cell proliferation and viability
The Hs578T (1.5 × 105), MDA-231 (1 × 104) and MCF-7
cells (1.5 × 105) were seeded on Falcon Multiwell™ 6-or
12-well plates (Becton Dickinson-BD Biosciences Discov-
ery Labware Franklin Lakes, NJ) and grown for 48–72 h.
The plates were washed with serum-free DMEM once and
then incubated for 1 h in DMEM with 2% FBS. Control
cells were treated with the vehicle only. Experimental cells
were incubated with 0.1, 1.0 and 10 μM NS-398 (N-(2-
cyclohexyloxy-4-nitrophenyl)-methanesulfonamide) or
10 μM niflumic acid (NA) for 24 h at 37°C in 5% CO2,
harvested and homogeneous cell suspension prepared
and counted. The number of viable cells was determined
by the dye exclusion method using erythrosin B and meas-
ured by hemacytometer counting.
Migration assay
Cell migration assays were performed using a modifica-
tion of the protocol described by Attiga et al [15]. The BD
Falcon Cell Culture Insert System containing PET (poly-
ethylene terephthalate) membranes with 8 μm pores (BD
Biosciences Discovery Labware Franklin Lakes, NJ) was
utilized in the assay. The Hs578T and MDA-231 cells were
harvested and resuspended into serum-free medium con-
taining NS-398 (0.1, 1.0 and 10 μM) or the vehicle. The
upper chamber of the insert was filled with 500 μl of the
cell and drug suspension (1 × 105 cells) and 1.5 ml of
(NIH/3T3) fibroblast-conditioned medium (FCM) was
added to the lower chamber. FCM served as the chemoat-
tractant. The conditioned medium was collected from
NIH 3T3 cells grown in serum-free DMEM after 24 h. The
plate was incubated in a humidified environment at 37°C
with 5% CO2 for 24 h. After incubation, the cells were
removed from upper surface of the membrane by wiping
with a moist cotton swab. The lower surface of the mem-
brane (cells that migrated) was stained for 10 min with
0.5% crystal violet in 25% methanol, rinsed with distilled
water to remove excess stain not absorbed by cells and air-
dried overnight. Digital images of the stained cells were
obtained prior to the extraction of dye. The crystal violet
was then extracted with 900 μl of 0.1 M sodium citrate in
Expression of COX-2 protein in different breast cancer cell linesFigure 1
Expression of COX-2 protein in different breast cancer cell 
lines. (Hs578T, MCF-7 and MDA-231). Protein was extracted 
with RIPA buffer and the expression of COX-2 protein 
detected by immunoblotting and then quantitated by densit-
ometry. Quantitated data were normalized to GAPDH. The 
relative units (RU) and ratio for the COX-2 and GAPDH 
bands for the different breast cancer cell lines were as fol-
lows: Hs578T (COX-2-57878/GAPDH-80182) = 0.7218, MCF-
7 (COX-2-5871/GAPDH-74734) = 0.05, MDA-231 (COX-2-
43861/GAPDH-61470) = 0.7135. Data for invasive cells lines 
were compared to poorly invasive cell line by one-way 
ANOVA followed by Student-Newman-Keuls test (,**p < 
0.01).Page 3 of 12
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(using Genova Life Science Analyser (Jenway Felsted, Eng-
land) spectrophotometer).
Wound migration assay
The Hs578T and MDA-231 cells (2.0 × 105) were seeded
into six-well plates and grown to 100% confluency. The
confluent cells were carefully wounded with sterile pol-
ished pasteur pipet tips and any cellular debris was
removed by washing with PBS. The wounded monolayers
were then incubated in the presence of NA (1.0 and 100
μM) for 0, 5 and 24 h time periods and digitally photo-
graphed. The distance between the wound edges was
measured using Adobe Photoshop 6.0.
Invasion assay
Cell invasion of the breast cancer cells were assessed by
using the BD BioCoat™ FluoroBlok™ Invasion System (BD
Biosciences Franklin, NJ) and procedures were followed
according to the manufacturer. Monolayer cells grown to
80% confluency and labeled in situ with 10 μg/ml of 1,1'-
didodecyl-3,3,3',3'-tetramethylindocarbocyanine per-
chlorate (DiIC12(3)) DiI fluorophore lipophilic tracer
(Molecular Probe, Invitrogen Carlsbad, CA) in medium
for 1 h at 37°C. The FluoroBlok Invasion insert plate was
rehydrated with warm PBS for 2 h at 37°C. Cells were har-
vested and resuspended in serum-free DMEM containing
NS-398 (0.1, 1.0 and 10 μM) or the vehicle. NIH/3T3
fibroblast-conditioned medium (FCM) 750 μl was added
to the lower chamber and the cell suspension (500 μl) was
added to the upper chamber. The system was incubated
22–24 h at 37°C and the fluorescence of the cells that
invaded was read directly with a GENios Pro fluorescence
plate reader (Tecan, San Jose, CA) at excitation/emission
wavelengths of 535/590 nm.
RNA isolation and real-time PCR
Total RNA was extracted from the Hs578T cells treated
with NS-398 and/or PGE2 (control cells received the vehi-
cle only), using the RNeasy mini Kit (Qiagen Valencia,
CA) according to the manufacturer's instructions. The
RNA was eluted and resuspended in RNA secure (Ambion
San Diego, CA). The concentration and purity of the RNA
was determined by measuring the absorbance at 260 nm
(A260) and determining the ratio of the readings at 260 nm
and 280 nm (A260/A280). Complimentary DNA (cDNA)
was prepared from 2 μg of RNA using Omniscript Reverse
Transcriptase (Qiagen Valencia, CA), 2.5 μM random
primers (Invitrogen Carlsbad, CA) and 0.5 U/μl RNase
Inhibitor (Ambion Austin, TX) and incubated at 37°C for
1 h.
The cDNA generated from the reverse transcriptase reac-
tion was amplified by real-time PCR using specific MMP-
(1, 2, 3, 9, 10, 11, 13, 14) and 18S primers and the SYBR
Green polymerase chain reaction master mix reagents. The
18S rRNA was used a as a standard. We performed the
PCR reaction according to the previously published meth-
ods in Singh et al [25]. The master mix for each cDNA
sample was composed of 5 μl of the diluted cDNA (20 μl
cDNA + 80 μl of nuclease-free water Ambion Austin, TX),
15 μl H2O, 5 μl 10 ng/ml reverse and forward primers,
and the 25 μl Q™SyBr Green Supermix (Bio-Rad Hercules,
CA). The reaction was performed according to the follow-
ing program: 10 min at 95°C for activating the polymer-
ase, the 40 cycles of 15 s at denaturation temperature of
95°C, 1 min of annealing at 60°C and the reaction was
held at 4°C. The relative MMP mRNA expression to the
18S rRNA copies was quantified by real-time PCR analysis
using the Bio-Rad Icycler and software (Bio-Rad Hercules,
CA).
Pro and active metalloproteinase protein detection
Cells (1 × 105) were seeded in 12-well plates and grown to
70–80% confluency. The plates were washed with serum-
free DMEM once and then incubated for 1 h in 1 ml of
DMEM with 2% FBS and either NS-398 or the vehicle. The
pro and active gelatinases (MMP-2 and MMP-9), colla-
genases (MMP-1 and MMP-13), and stromelysins (MMP-
3 and MMP-10) levels released in the media were meas-
ured using a Quantikine colorimetric and Fluorokine
fluorometric enzyme immunoassay (EIA) kit (R&D Sys-
tems Minneapolis, MN) using the manufacturer's instruc-
tions. After 24 h, the media were collected in
microcentrifuge tubes and centrifuged for 10 min at
10,000 g in order to remove particulates. The samples
were stored frozen at -80°C prior to the assay. The sam-
ples and MMP standards were incubated on a pre-coated
polyclonal or monoclonal MMP antibody 96 well-plate
for 2 h on a shaker at room temperature. The intensity of
color on the Quantikine EIA plates was determined by
Spectra Max 190 and SOFTmax-Pro 4.3 Life Sciences Ed.
(Molecular Devices Sunnyvale, CA) at a wavelength of
450 nm with a correction of 540 nm. The fluorescent sig-
nal in the sample on the Fluorokine EIA wells was deter-
mined by the GENios Pro fluorescence plate reader
(Tecan, San Jose, CA) at excitation/emission wavelengths
of 340 nm/465 nm.
Statistical analysis
Statistical significance was determined by one-way
ANOVA with Student-Newman-Keuls post test was per-
formed using GraphPad InStat v3.00. The data was
expressed as the mean ± S.E.; significance was achieved at
p values < 0.05.
Results
Growth inhibition of COX-2 expressing breast cancer cells
We treated the Hs578T, MDA-231 and MCF-7 breast can-
cer cells with NS-398 and NA for 24 h and examined thePage 4 of 12
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2 expressing cell lines, Hs578T and MDA-231 with 0.1,
1.0, 10 μM NS-398 and NA impeded the growth of the
cells. NS-398 resulted in a 30% growth inhibition of
Hs578T cells (p < 0.01) and 40% growth inhibition of
MDA-23l cells (p < 0.05) at 0.1 μM (Fig. 2). We also found
a 37% inhibition (p < 0.05) of MDA-231 growth by 10
μM NA compared to the control (Fig. 2b). The MCF-7 cells
did not show a difference in growth when treated with NS-
398 (data not shown). The COX-2 inhibitors did not sig-
nificantly affect the cell viability. There was 85%, or
higher, cell viability seen after treatment with COX-2
inhibitors, up to 10 μM indicated no cytotoxicity.
Inhibition of cell migration and invasion with a COX-2 
inhibitor
We evaluated the effect of the COX-2 inhibitors on the cell
motility and invasiveness of MDA-231 and Hs578T breast
cancer cells. Cell motility and invasion are a measure of
metastatic potential cancer cells. Treatment with 1.0 μM
NS-398 inhibited MDA-231 cell motility by 35% (p <
0.05) (Fig. 3a). Confluent MDA-231 cells subjected to the
scratch wound assay in the presence of 1.0 and 100 μM
NA showed a significant delay in cells moving into the
injury area. The control cells migrated into the wound
area by 5 h to such an extent that the wound edges were
indistinguishable, whereas the experimental group of cells
did not migrate into and completely close the wound area
until 24 h (Fig. 3b).
Figure 4a shows that the motility of Hs578T cells was sig-
nificantly decreased by 21% (p < 0.05) by 10 μM NS-398
when compared to the control. Inhibition of Hs578T cell
motility by COX-2 inhibitors was also confirmed by the
scratch wound assay. Figure 4b shows that Hs578T wound
incubation with 1 and 100 μM NA resulted in a significant
delay in cell migration compared to the control (Fig. 4b).
Prior to the migration phase of metastasis, breast cancer
cells must invade the basement membrane and the extra-
cellular matrix. We measured the invasive ability of breast
cancer cells on Matrigel coated membranes. Invasion of
MDA-231 cells was inhibited by 11% in response to 10
μM NS-398 (p < 0.01) (Fig. 5a). We found a 21% decrease
of the invasion of Hs578T cells by 10 μM NS-398 (Fig.
5b).
Effect of COX-2 inhibition on the secretion of MMPs
We assessed the dose-dependent effects of NS-398 on
MMP secretion by Hs578T and MDA-231 cells. After 24 h,
there was a 67% decrease in MMP-1, 45% in MMP-2 and
65% in MMP-3 secretion by Hs578T cells treated with 100
μM NS-398 (Fig. 6). We also observed a significant reduc-
tion (66%) of MMP-13 when the cells were treated with
50 μM NS-398 (Fig. 6d). In contrast, MMP-9 and MMP-10
were undetectable in the media of Hs578T cells, suggest-
ing that the cells did not secrete these MMPs.
Out of the six MMPs assessed by EIA, we were only able to
detect the presence of MMP-1 and MMP-9 in the media of
MDA-231 cells. There was about a 20% decrease for both
MMP-1 and MMP-9 secreted by these cells treated with 50
μM NS-398 (Fig. 7). We found a 15% reduction in active
MMP-2 and 20–30% reduction in active MMP-9 by
immunoblotting analysis for MDA-231 cells treated with
the NA or NS-398, respectively (data not shown).
Effect of COX-2 inhibitors on breast cancer cell proliferationFigure 2
Effect of COX-2 inhibitors on breast cancer cell prolifera-
tion. A) 1 × 104 MDA-231 cells and B) 1.5 × 105 Hs578T 
were seeded, grown for 48 h and then treated with COX-2 
inhibitors (NS-398 and Niflumic Acid) or the vehicle for 24 h. 
Cells were harvested and counted as described in the Meth-
ods. Data for treated cells were compared to untreated con-
trols by one-way ANOVA followed by Student-Newman-
Keuls test (*p < 0.05, **p < 0.01).Page 5 of 12
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COX-2 inhibitor
Table 1 shows detectable basal levels of MMPs (1, 2, 3, 9,
10, 11, 13 and 14) in the COX-2 expressing cell line,
Hs578T before treatment with NS-398 with or without
PGE2. MMP-2 and -3 exhibited the highest number of
transcripts produced by the cells compared to the other
MMPs at basal levels which corresponds with the trend of
the active protein secreted by the Hs578T. The MMPs that
displayed barely detectable transcripts at basal levels were
MMP-10 and -14. This is consistent with EIA results, when
active MMP-10 was not detected in the media. We
observed a significant 2 log-fold and 4 log-fold decline in
MMP-2 and MMP-3 expression levels when the cells were
treated with 10 μM NS-398. MMP 1, 9, 11 and 14 were
either below detection limits or at barely detectable levels
when the Hs578T cells were treated with 10 and 100 μM
NS-398. One of the products of COX-2 is PGE2; this pros-
taglandin reversed the inhibitory effect of NS-398 on the
MMP mRNA expression. In some cases PGE2 actually
resulted in MMP levels that were greater than control lev-
els. These data suggests that NS-398 reduced MMP mRNA
expression and that PGE2 may promote the invasion of
breast cancer cells through enhancing MMP secretion.
Discussion
Prognosis of breast cancer patients is strongly correlated
with the stage of the cancer at the initial diagnosis. If the
The effect of COX-2 inhibition on the migration of MDA-231 cellsFigure 3
The effect of COX-2 inhibition on the migration of MDA-231 cells. A) Cells (1 × 105) were placed in the upper chamber 
inserts with or without NS-398 in serum-free DMEM and allowed to migrate for 24 h. FCM was used as a chemoattractant to 
stimulate the migration of the cells. B) Wound migration assay. Confluent MDA-231 cells cultured in six well dishes were 
wounded with a sterile pipette tip and then incubated with or without Niflumic Acid for 24 h. Photographs were taken with a 
phase contrast microscope and measurements with Adobe photoshop 6.0. Values were significant (*p < 0.05, **p < 0.01) when 
compared to untreated controls (0 μM NA or NS-398).Page 6 of 12
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The effect of COX-2 inhibition on migration of Hs578T cellsFigure 4
The effect of COX-2 inhibition on migration of Hs578T cells. A) Cells (1 × 105) were placed in the upper chamber inserts with 
or without NS-398 in serum-free DMEM and allowed to migrate for 24 h. FCM was used as a chemoattractant to stimulate the 
migration of the cells. B) Wound migration assay. Confluent Hs578T cells cultured in six well dishes were wounded with a 
sterile pipette tip and then incubated with or without Niflumic Acid for 24 h. Photographs were taken with a phase contrast 
microscope and measurements with Adobe photoshop 6.0. Values were significant (*p < 0.05) when compared to untreated 
controls (0 μM NA or NS-398).
Table 1: Effect of COX-2 Inhibitor and PGE2 on MMP mRNA Expression. Expression of MMP mRNA in Hs578T cells in the presence of 
NS-398 with or without 1 μM PGE2. Hs578T cells were cultured in the presence NS-398 with or without PGE2 for 24 h. The relative 
quantitation of the gene expression of the MMP mRNA was calculated against an 18S rRNA standard. The number of copies of MMP 
mRNA per 106 copies of 18S rRNA was determined by real time-PCR according to the methods of Singh et al [25]. The real-time PCR 
analysis was capable of detecting >5 copies of mRNA. Hence, copy numbers <5 were below detection (BD) limits. Significance (n = 4, 
*p < 0.05) was determined by comparing the treated Hs578T cells to the untreated control. #The data in this column has an n = 2 and 
is listed to show the direction of the effect of PGE2.
Type of MMP NS-398 (μM) NS-398/PGE2 (μM) #
Control 1 10 100 1.0/1.0
MMP-1 1.04 × 102 BD BD BD 3.58 × 103
MMP-2 2.09 × 105 3.93 × 103* 3.87 × 102* 1.06 × 103* 3.11 × 107
MMP-3 3.42 × 105 5.73 × 102* 28.0* 1.08 × 102* 3.26 × 1013
MMP-9 16.4 BD BD BD 1.06 × 105
MMP-10 BD BD BD BD 38.4
MMP-11 8.31 × 103 6.92 BD BD 1.85 × 109
MMP-13 3.93 × 102 57.9 11.7 4.83 1.70 × 106
MMP-14 BD BD BD BD 4.53 × 104
BMC Cancer 2006, 6:181 http://www.biomedcentral.com/1471-2407/6/181cancer is only detected when there is an invasive state,
then the prognosis is poorer. In fact, 90% of patients that
die of breast carcinoma have bone metastases [26]. COX-
2 expression may serve as a biomarker that could be
assessed to predict the possible progression of the disease.
Additionally, understanding the mechanistic and molecu-
lar role of COX-2 in tumor progression and the complex
multi-step metastatic process can aid in combating breast
cancer mortality. In order for metastasis to occur, angio-
genesis, cell attachment, dissociation, proteolysis of the
matrix and motility are essential steps. Several studies
have reported that COX-2 is involved in these complex
steps. In this study, we examined the role of COX-2 in
breast cancer cell proliferation, invasion and motility in
an attempt to improve our understanding of the molecu-
lar mechanism of breast cancer metastasis.
Several studies have demonstrated the efficacy of non-
selective and selective COX inhibitors on the proliferation
of breast cancer cells, using murine cancer models and
human cancer cell lines. Harris et al. [27] evaluated the
chemopreventive potential of celecoxib and ibuprofen in
the DMBA (7, 12-dimethyl-benz [a] anthracene) model of
breast cancer in Sprague-Dawley rats. Both drugs signifi-
cantly reduced tumor incidence, volume and burden. At
40 and 60 μM, celecoxib suppressed the growth and pro-
liferation in breast cancer cell lines, MDA-231 and MDA-
435 by inducing apoptosis and cell cycle arrest at the G0/
G1 phase, respectively [28]. Other studies have suggested
that high concentrations of COX inhibitors (over 25 μM)
promote apoptosis in cancer cells [29-32]. Although we
did not detect any effects that may be independent of
COX inhibition, other groups have demonstrated that
high concentrations of non-selective and selective COX-2
inhibitors may reduce the proliferation or modulate the
cell cycle genes in cancer cells independent of COX-2
expression [33-35]. Elder et al. [34] found a dose-depend-
ent anti-proliferative effect of NS-398 in the colorectal
cancer cells, S/KS, that does not express detectable levels
of COX-2. Both NS-398 and nimesulide induced p21 gene
promoter activity in non-small cell lung cancer cells but
COX-2 siRNA did not affect the expression of p21 [35].
Based on these prior studies using the selective COX-2
inhibitors, we selected a concentration range of 0.1–100
μM to use in our experimental studies. We found that the
lower concentrations significantly affected the breast can-
cer cells to about the same extent as the higher concentra-
tions [36-38]. The levels that we used are in the achievable
range for humans that have been reported for clinically
available selective COX-2 inhibitors used as drugs, e.g.,
celecoxib and meloxicam.
In this study, we demonstrated the anti-proliferative
effects of the selective COX-2 inhibitors, NS-398 and NA
in the both COX-2 expressing cell lines, MDA-231 and
Hs578T. Our findings indicate that these selective inhibi-
tors will only retard the growth of breast cancer cells that
express COX-2. The inhibition of Hs578T cell growth
reached a plateau around 1.0 μM indicating there would
be no further decrease at higher concentrations. While a
few studies may show that MCF-7 cell growth is inhibited
by COX-2 inhibitors [39,40], we found that MCF-7 cancer
cells were not affected by the COX-2 inhibitors (data not
shown). The inhibition of cancer cell proliferation by
COX-2 inhibitors has also been reported for prostate and
colon cancer models [41-43].
The effect of NS-398 on invasion of MDA-231 (A) and Hs578T (B) cellsFigure 5
The effect of NS-398 on invasion of MDA-231 (A) and 
Hs578T (B) cells. Cells (1 × 105) were placed in the upper 
chamber of the BD BioCoat Tumor Invasion FluoroBlok Sys-
tem with and without NS-398 in serum-free DMEM and 
allowed to invade for 24 h. FCM was used as a chemoattract-
ant to stimulate the invasion of the cells. Values were signifi-
cant (*p < 0.05, **p < 0.01) when compared to untreated 
controls (0 μM NS-398).Page 8 of 12
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which is necessary for a cell to move through the extracel-
lular matrix and enter the circulation where it can travel to
a distant site. We were able to demonstrate the inhibitory
effect of the selective inhibitors on the motility of the
Hs578T and MDA-231 cells. Similarly, Singh et al. [6]
showed the addition of 50 μM NS-398 inhibited MDA-
231 cell migration by 47%. Our results also suggest even
a lower concentration (i.e. 0.1 μM) of NS-398 causes a
decline in the cell motility of the MDA-231 cells. This data
confirms that COX-2 activity mediates the chemotaxis of
breast cancer cells across a membrane toward a chemoat-
tractant.
With Matrigel, we found that NS-398 partially attenuated
the invasive ability of the COX-2-expressing cell lines.
Compared to the control, 10 μM NS-398 reduced the
invasion of both of the COX-2-expressing cell lines by 10–
20%, which is consistent with the findings of Singh et al
[6]. These researchers showed that the addition of a higher
level of NS-398 (50 μM) inhibited MDA-231 invasion
through Matrigel by 54%.
In order for the cells to invade and migrate through the
basement membrane (i.e., Matrigel), proteolysis of the
extracellular matrix must occur. This is accomplished by
the secretion and activation of MMPs, which will degrade
all extracellular matrix components (e.g., laminin, colla-
gen (all types), entactin and a number of other factors,
including growth factors (TGF-β and FGF) and cytokines).
The association of MMPs with tumor progression is well
documented [7,44,45]. The expression of MMPs, particu-
The effect of NS-398 on metalloproteinase release in culture media by Hs578T cellsFigure 6
The effect of NS-398 on metalloproteinase release in culture media by Hs578T cells. The cells were cultured in the presence 
or absence of increasing doses of NS-398 for 24 h. The levels of the pro and active form of MMPs-1, 2, 3, 9, 10 and 13 were 
measured in the culture media of treated cells by EIA. A) MMP-1 B) MMP-2 C) MMP-3 D) MMP-13. MMP-9 and MMP-10 were 
not detected in Hs578T media. Values were significant (*p < 0.05) when compared to untreated controls (0 μM NS-398).Page 9 of 12
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ciated with high potential of metastasis in several human
carcinomas including breast cancer [46,47]. In this study,
we also determined the mediation of MMP expression
and secretion by COX-2, using an inhibitor approach.
We found a dose-dependent inhibitory effect of NS-398
on the secretion of both pro and active forms of MMPs (1,
2, 3, and 13) in Hs578T cells, which highly express COX-
2. With 1 μM of NS-398 treatment, we found that MMP
secretion levels decreased by 50% or higher. Surprisingly,
we did not detect quantifiable levels of the pro and active
MMP-9 which has been suggested to be highly expressed
by invasive breast carcinomas [48]. We did observe very
low MMP-9 mRNA expression in control Hs578T cells,
which could account for these results. We were also able
to detect an effect of COX-2 inhibition on the expression
of MMP mRNAs. NS-398, 1 μM, decreased MMP mRNA
expression to barely detectable levels; there was little
change in expression with 10 or 100 μM NS-398. This sug-
gest that either there is not dose-dependency or there is a
threshold effect of NS-398 on MMP mRNA levels, i.e., a
minimum level of COX-2 activity is required to induce the
expression of MMP mRNA that we observed in control
cells. The 1 μM concentration is in the range of the IC50 of
NS-398 for the inhibition of COX-2 enzyme activity
reported by the manufacturer and by previous studies
[49,50], which may account for the drastic decrease it
caused in MMP mRNA expression.
Increased levels of various prostaglandins, especially
PGE2, have been associated with many different invasive
cancers [7,51-53]. Our position is that the ability of NS-
398 to produce an anti-invasive effect on cancer cell lines
is due to the down-regulation of prostaglandin produc-
tion, which facilitates the functions of COX-2. Our find-
ings also show that COX-2 may exert a tumorigenic effect
through PGE2. By inhibiting the COX-2 activity in the
Hs578T cells with 1–10 μM NS-398, we were able to
reduce the endogenous PGE2 levels by 75% (unpublished
observations). The addition of exogenous PGE2 com-
pletely reversed the inhibitory effect of with NS-398 on
the expression of all MMP mRNAs by Hs578T cells. In
fact, PGE2 treatment of the NS-398 pre-treated Hs578T
cells resulted in increased MMP expression, which sur-
passed basal levels. We also found that NS-398 treatment
of MDA-231 also resulted in the inhibition of the pro and
active MMPs (1, 2, and 9). Our preliminary studies
showed that adding exogenous PGE2 to the control MDA-
231 cells did not affect or may have decreased the secre-
tion of MMPs. These data suggest that exogenous PGE2, by
itself, can not modulate the increase in MMP secretion
without a reduction in the endogenous PGE2 levels. Sev-
eral other studies have also implicated PGE2 in the activa-
tion of COX-2 gene expression, which could lead to an
increase in active COX-2 and subsequent higher MMP
expression [54,55]. Pan et al. [56] showed that NS-398
treatment resulted in a suppression in MMP-2 promoter
activity, MMP mRNA and active MMP-2 protein by the
A549 lung cancer cell line. Inhibition of the MMP-2 pro-
moter activity by NS-398 was partially reversed by exoge-
nous PGE2. Other studies using a human prostate cancer
cell line (DU-145) or a colorectal cancer cell line (MC-
26), treated with 10 and 100 μM NS-398, reported a
reduction in the release of pro and active MMP-2 and
MMP-9 in the culture media [15,38]. However, the under-
lying mechanism for how PGE2 up-regulates the expres-
sion of MMPs is not known. Further investigations are
The effect of NS-398 on metalloproteinase release in culture media by MDA-2 1 cellsFigure 7
The effect of NS-398 on metalloproteinase release in culture 
media by MDA-231 cells. These cells were cultured in the 
presence or absence of increasing concentrations of NS-398 
for 24 h. The secretion of the pro and active form of MMPs 
was determined by EIA. A) MMP-1 B) MMP-9. MMP-2, MMP-
3, MMP-10 and MMP-13 were not detected in MDA-231 
media. Values were significant (*p < 0.05) when compared to 
untreated controls (0 μM NS-398).Page 10 of 12
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observed in our study.
Contrary to our expectation, we did not see exactly the
same MMPs secreted by both of the COX-2-expressing cell
lines. We suspect that the difference could be a result of
the heterogeneity of the Hs578T cell line or the cell's
response to its extracellular environment. The time period
used for transcription of the various MMPs in these cells
may also explain some of the variability observed. In an in
vivo system, the stroma of breast carcinomas may also
secrete MMPs in response to high COX-2 expression by
the breast tumor, which would also aid in tumor cell inva-
sion. To our knowledge, we are the first to report that the
inhibition of COX-2 reduces both MMPs mRNA expres-
sion and secretion of pro and active MMPs in breast can-
cer cell lines where COX-2 is highly expressed. Our study
suggests that the MMPs may promote some of the delete-
rious effects of COX-2, and could possibly be studied as a
useful target for combination chemotherapy for breast
cancer patients that overexpress COX-2.
Conclusion
Using an inhibitory approach, we examined the involve-
ment of COX-2 activity promoting breast cancer meta-
static behavior. In this report, we confirm that the
expression and activity of COX-2 may be a required com-
ponent for breast cancer cell proliferation, motility and
invasion. In our experiments, we showed that treating
breast cancer cell lines that express COX-2 with a COX-2
inhibitor decreased proliferation, migration, invasion,
and MMP production. Furthermore, we report that PGE2
may mediate the effects COX-2 activity by activating sign-
aling pathways via PGE2 (EP) receptors. However, exoge-
nous PGE2 alone was not able to induce a number of
changes seen by exogenous PGE2 when COX-2 was first
inhibited. Since currently there is no clear understanding
of the mechanism by which COX-2 facilitates the progres-
sion of cancer, our studies suggest a strategy for assessing
the COX-2 pathway through elucidating possible down-
stream signaling mediators that have effects on the migra-
tion, invasion and expression of MMPs by highly invasive
breast cancer cell lines.
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